Idiopathic Pulmonary Fibrosis

The disease is idiopathic, so no definite cause is established in the supplied grounding. The literature grounding indicates that its etiology is complex and includes heritable factors, with both rare genetic variants and common SNPs contributing to pulmonary fibrosis risk. The MUC5B promoter variant is specifically highlighted as a genetic contributor associated with increased risk.

The disease is characterized by progressive fibrotic remodeling of the lung interstitium, with patchy collagen deposition and fibroblast proliferation. Immune dysregulation is implicated, including uncontrolled immune responses and the activity of innate and adaptive immune cells in driving onset and progression. Macrophage polarization is also described as important, with M1 macrophages contributing to early inflammatory injury and M2 macrophages supporting tissue repair and fibrosis.

Older adult age is part of the typical clinical profile, with onset usually between 50 and 70 years of age. Genetic susceptibility increases risk, including rare genetic variants, common SNPs, and the MUC5B promoter variant. The supplied grounding also indicates that heritable factors contribute to disease risk, but does not support additional specific environmental or clinical risk factors.

The supplied grounding supports pharmacological treatment for IPF but does not provide specific drug names or regimens. It indicates that current management includes pharmacological therapies and emerging immunotherapy, with interest in targeted immunomodulatory approaches. At the modality level, treatment is described as disease-directed therapy aimed at slowing progression rather than reversing established fibrosis.